DK1814880T3 - Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed - Google Patents

Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed

Info

Publication number
DK1814880T3
DK1814880T3 DK05808135T DK05808135T DK1814880T3 DK 1814880 T3 DK1814880 T3 DK 1814880T3 DK 05808135 T DK05808135 T DK 05808135T DK 05808135 T DK05808135 T DK 05808135T DK 1814880 T3 DK1814880 T3 DK 1814880T3
Authority
DK
Denmark
Prior art keywords
imidazo
compositions
associated therewith
pyridine compounds
methods associated
Prior art date
Application number
DK05808135T
Other languages
Danish (da)
English (en)
Inventor
Antonio Guglietta
Jose Luis Falce
Albert Palomer
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Application granted granted Critical
Publication of DK1814880T3 publication Critical patent/DK1814880T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK05808135T 2004-11-11 2005-11-04 Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed DK1814880T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105698 2004-11-11
PCT/EP2005/055753 WO2006051063A1 (en) 2004-11-11 2005-11-04 Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto

Publications (1)

Publication Number Publication Date
DK1814880T3 true DK1814880T3 (da) 2009-05-18

Family

ID=34929843

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05808135T DK1814880T3 (da) 2004-11-11 2005-11-04 Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed

Country Status (24)

Country Link
US (1) US20080200473A1 (https=)
EP (1) EP1814880B1 (https=)
JP (1) JP2008519805A (https=)
KR (1) KR20070084026A (https=)
CN (1) CN101065377B (https=)
AR (1) AR051626A1 (https=)
AT (1) ATE421962T1 (https=)
AU (1) AU2005303811A1 (https=)
BR (1) BRPI0517796A (https=)
CA (1) CA2585315A1 (https=)
DE (1) DE602005012598D1 (https=)
DK (1) DK1814880T3 (https=)
ES (1) ES2321858T3 (https=)
IL (1) IL182963A0 (https=)
MX (1) MX2007005611A (https=)
NO (1) NO20072831L (https=)
PA (1) PA8652101A1 (https=)
PE (1) PE20060967A1 (https=)
PL (1) PL1814880T3 (https=)
PT (1) PT1814880E (https=)
RU (1) RU2007121864A (https=)
TW (1) TWI357412B (https=)
UY (1) UY29204A1 (https=)
WO (1) WO2006051063A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
MX2008014796A (es) * 2006-05-31 2008-12-02 Hoffmann La Roche Derivados de aril-4-etinil-isoxazol.
AU2007288124B2 (en) * 2006-08-24 2013-04-04 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
AU2009239430B2 (en) 2008-04-21 2015-01-22 Signum Biosciences, Inc. Compounds, compositions and methods for making the same
CA2724842A1 (en) 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
WO2010045615A2 (en) 2008-10-16 2010-04-22 Cenomed Biosciences, Llc Treatment of organophosphate exposure with ocinaplon
EP2376490B1 (en) * 2008-12-04 2013-01-23 Proximagen Limited Imidazopyridine compounds
EP2496578A4 (en) 2009-11-05 2013-08-21 Univ Notre Dame Du Lac IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF
WO2012036278A1 (ja) * 2010-09-17 2012-03-22 大正製薬株式会社 グリシントランスポーター阻害物質
CN108348510B (zh) 2015-09-17 2022-01-04 圣母大学 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
CN106906486B (zh) * 2017-02-22 2018-12-11 华南理工大学 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
KR20260004434A (ko) * 2023-04-24 2026-01-08 상하이 에스아이엠알 바이오테크놀로지 컴퍼니 리미티드 이미다조피리딘 또는 이미다조피라진 화합물, 이의 제조 방법, 약학 조성물 및 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) * 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
ES2032455T3 (es) * 1986-01-22 1993-02-16 Synthelabo Procedimiento para preparar derivados de 3-acilaminometil-imidazo (-1,2-a)piridinas.
FR2593181B1 (fr) * 1986-01-22 1988-04-01 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US20040204443A1 (en) * 2003-01-27 2004-10-14 Arthur Zaks Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives

Also Published As

Publication number Publication date
TWI357412B (en) 2012-02-01
UY29204A1 (es) 2006-01-31
PA8652101A1 (es) 2006-10-13
NO20072831L (no) 2007-08-01
CN101065377B (zh) 2011-07-27
US20080200473A1 (en) 2008-08-21
TW200624432A (en) 2006-07-16
RU2007121864A (ru) 2008-12-20
ATE421962T1 (de) 2009-02-15
JP2008519805A (ja) 2008-06-12
EP1814880A1 (en) 2007-08-08
CA2585315A1 (en) 2006-05-18
PL1814880T3 (pl) 2009-07-31
CN101065377A (zh) 2007-10-31
AU2005303811A1 (en) 2006-05-18
EP1814880B1 (en) 2009-01-28
AR051626A1 (es) 2007-01-24
ES2321858T3 (es) 2009-06-12
IL182963A0 (en) 2007-08-19
WO2006051063A1 (en) 2006-05-18
PT1814880E (pt) 2009-04-23
PE20060967A1 (es) 2006-09-20
DE602005012598D1 (de) 2009-03-19
KR20070084026A (ko) 2007-08-24
BRPI0517796A (pt) 2008-10-28
MX2007005611A (es) 2007-07-11

Similar Documents

Publication Publication Date Title
DK1814880T3 (da) Imidazo[1,2-a]pyridinforbindelser, og sammensætninger, anvendelser og fremgangsmåder, der er forbundet dermed
IL184717A0 (en) Imidazo (1,2-a)pyridine compounds as vegf-r2 inhibitors
SI1581532T1 (sl) Pirazolo-3,4-b piridinske spojine in njihova uporaba kot zaviralci fosfodiesteraze
DK1966202T3 (da) Heteroarylsubstituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-d]pyrimidiner som Januskinaseinhibitorer
ZA200802497B (en) Imidazo [1,2-A] pyridine having anti-cell-proliferation actvity
ZA200703912B (en) 3-arylamino pyridine derivatives
AP2007003887A0 (en) Pyridine derivatives
BRPI0822237A2 (pt) Compostos de imidazo [1,2-a] piridina
ZA201202025B (en) INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLO[2,3-b] PYRIDINE DERIVATIVES
IL201009A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
DK1761542T3 (da) Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
IS7939A (is) Pýrasólpýridín afleiður
EP1741703A4 (en) pyridone
ZA200805354B (en) Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives
DK1888580T3 (da) Pyrido[2,3-D]pyrimidiner, der er egnede som HCV-hæmmere, og fremgangsmåde til fremstillingen af disse
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
ZA200609765B (en) Therapeutic compounds: pyridine as scaffoid
ATE433977T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido 1,2-a pyrimidin-4-on-derivate
AU2003255323A8 (en) Imidazo`1,2-a pyridines
IL179605A0 (en) Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists
NL1033403A1 (nl) Therapeutische pyrazolo[3,4-b]pyridinen en indazolen.
IL190989A0 (en) Thiazolo [4,5-c]pyridine derivatives
DK1899343T3 (da) Halogenerede pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelser som GABA-A-receptorligand, sammensætninger og mellemprodukter
DK2059521T3 (da) Pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelse og sammensætninger
DK1957490T3 (da) Hidtil ukendte indolizinderivater, fremgangsmåde til fremstilling deraf og terapeutiske sammensætninger, der omfatter samme